Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abciximab i.v. vs i.c. in STEMI Patients Undergoing Primary PCI
NCT00299377Phase 3Completed
- Sponsor
- Leipzig University
- Start
- Jan 2006
- Primary completion
- Nov 2007
- Modality
- Antibody Fragments, Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised trial of abciximab in myocardial infarction (MI) (2 arms), sponsored by Leipzig University. Primary endpoints: Infarct Size and Microvascular Obstruction. Started Jan 2006; status: completed.
02
Drugs
abciximab
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on NCT00299377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00299377.